Calciphylaxis is a rare, usually fatal vasculopathic disorder characterized by cutaneous ischemia and necrosis due to calcification of arterioles. Although calciphylaxis is most frequently associated with end-stage renal disease (ESRD) and secondary hyperparathyroidism, it has been reported infrequently among patients on warfarin. No standard treatment has been established for atypical calciphylaxis; however, a potentially beneficial treatment is hyperbaric oxygen therapy (HBOT). A high degree of clinical suspicion, early diagnosis, and understanding the pathophysiology of this disease promotes the optimal management of this extremely morbid and often fatal condition. Case Report: We present a 63-year-old Polynesian woman with biopsy-proven calciphylaxis in the absence of ESRD or elevated serum calcium levels while taking warfarin. Therapeutic dose enoxaparin was substituted for warfarin and she received 40 sessions of HBOT during which lower extremity ulcers resolved. Discussion: Warfarin has been implicated when calciphylaxis presents in an atypical fashion. No guidelines exist for treatment of atypical calciphylaxis in the setting of concomitant warfarin therapy. Up to 80% of calciphylaxis patients die within 1 year of diagnosis. Our patient was changed to low-molecular-weight heparin and received HBOT. Conclusion: We present what we believe is the first case of atypical calciphylaxis thought to be attributable to warfarin treated with a therapeutic substitution of anticoagulant and HBOT leading to resolution of cutaneous lesions.
Introduction
Calciphylaxis, also known as calcific uremic arteriolopathy, is a rare, usually fatal vasculopathic disorder characterized by cutaneous ischemia and necrosis due to calcification, intimal fibroplasia, and thrombosis of medium-and small-sized arterioles. 1 It most often affects patients with end-stage kidney failure and high serum levels of calcium due to secondary hyperparathyroidism. 2 There are an increasing number of case reports of patients with calciphylaxis in the absence of end-stage renal disease (ESRD) and normal serum calcium levels. [2] [3] [4] [5] We present what we believe is the first case of atypical calciphylaxis attributable to warfarin treated successfully with a therapeutic substitution of anticoagulant and hyperbaric oxygen therapy (HBOT).
Case Presentation
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The author received no financial support for the research and/or authorship of this article. dependent diabetes, coronary artery disease, gout, obstructive sleep apnea, degenerative joint disease, and morbid obesity. She has no history of malignancy or liver disease. She has neither used tobacco nor does she drink alcohol. She presented with a 2-week history of a painful enlarging ulcer of the left lower extremity. She further described a 3-month history of a purplish mottled discoloration of the skin that was lacy in appearance ( Figure 1 ). She had visited the emergency department with these complaints 1 week prior to presenting to our clinic and was treated for suspected cellulitis with a 7-day course of intravenous vancomycin. This was followed by a 10-day course of cephalexin 500 mg four times daily (QID) prescribed by a dermatologist at the time of biopsy of the lesion as noted below. Her medicines otherwise included warfarin 2.5 mg by mouth daily 4 times a week and 2 tabs 3 days per week titrated to a target INR 2.5 (International Normalized Ratio) (range 2-3), allopurinol, vitamin B12, tolterodine, hydrochlorothiazide, losartan, amlodipine, omeprazole, clopidogrel, metoprolol, and simvastatin.
On presentation to our clinic on August 23, 2008, the patient had a temperature of 37 C, blood pressure of 145/62 mm Hg, pulse of 61 beats per minute (bpm), and body mass index (BMI) of 39. She presented in obvious discomfort. Her examination was remarkable for the presence of normal pedal pulses and capillary refill bilaterally. A large irregular wound and surrounding erythema with eschar on the left calf (measurements 16 Â 14 cm; Figure 2 ), as well as a lacy purplish mottled discoloration of the skin on the right leg ( Figure 1 ), were noted.
Laboratory data showed a serum creatinine of 1.07 (CrCl [creatinine clearance] > 60 mL/min), calcium of 8.6 mg/dL, phosphorous 3.7 (calciumphosphorous product ¼ 31.8), total cholesterol 189 mg/dL, albumin 3.5 g/dL, white blood cell (WBC) of 6.5 k/mL, hemoglobin of 11.2 g/dL, MCV (mean corpuscular volume) of 90.6 fL, platelet count of 274 000, negative cryoglobulins, negative anticardiolipin antibodies, and normal protein C and S levels while off warfarin therapy, and a slightly elevated parathyroid hormone of 90 pg/mL (normal ¼ 15-75 pg/mL).
Magnetic resonance imaging (MRI) of lower extremity showed superficial cellulitis with skin ulcerations but no subcutaneous abscess. There were no destructive bone lesions or intraosseous abscesses. Noninvasive arterial vascular examination demonstrated no significant occlusive disease of the large vessels of either lower extremity.
A 4-mm punch biopsy of the left leg wound was performed, which showed ''skin and soft tissue with calcification of medium-sized and thin-walled blood vessels including patchy vascular damage, consistent with calciphylaxis'' ( Figure 3 ). No intra-arterial cholesterol crystals were observed.
Clinical Course
On initial evaluation in our clinic, warfarin was discontinued and the patient was placed on enoxaparin 1 mg/kg twice daily. The patient was referred for evaluation and treatment to the wound care and hyperbaric oxygen service. The patient received weekly wound care evaluation and occasional sharp debridement as tolerated. Pentoxifylline was prescribed but discontinued shortly thereafter as the patient experienced intolerable nausea. No additional antibiotics were prescribed. Over an 8-week period, the patient received 40 HBOT with 100% oxygen at 2.0 ATA (atmosphere absolute) for 90 minutes per treatment without complication. Following 1 week of HBOT, the wound had decreased in size to 14 Â 12 cm with a wound bed consisting of 80% eschar and 20% granulation tissue. After 4 weeks of HBOT, 60% granulation and 40% eschar was noted. Only 2 punctuate lesions remained after 15 weeks, and the lesion was completely resolved by 20 weeks after initiation of HBOT ( Figure 4 ). The patient has been pain-free and without signs of infection or recurrent lesions during the subsequent 21 months of follow-up.
Discussion
Calciphylaxis is a disease of the vasculature resulting in mural calcification and ischemia distal to the affected vessels. Mural calcific and fibrous expansion involves the capillaries, venules, arterioles, and small arteries of the dermis and subcutaneous fat. Elevated calcium and phosphorus levels have long been implicated in the development of calciphylaxis, and an elevated calcium-phosphorous product is a previously described risk. [5] [6] [7] [8] [9] [10] [11] This is well characterized among patients with ESRD. Our patient was noted to have a normal calcium-phosphorous product. Markedly elevated serum parathyroid hormone (PTH) is often present among patients with calciphylaxis. In 1 study, the mean serum-intact PTH among 21 patients with calciphylaxis was 440 pg/dL. 12 Our patient presented with neither a highly elevated PTH nor ESRD. Other risk factors that have been described include liver disease, systemic corticosteroid use, white race, female gender, hypoalbuminemia, obesity, and elevation in alkaline phosphatase. 5, 6, 11, 13 Warfarin has been reported to cause calciphylaxis through an interaction with the inhibitor of calcification, matrix gla protein (MGP). 2, 8, 14, 15 Matrix gla protein is an 84 amino acid vitamin K-dependent protein that requires carboxylation of glutamate residues in positions 2, 37, 41, 47, and 52 for its antimineralization properties. 15, 16 Although MGP is synthesized in kidney, cartilage, lung, heart, and vascular smooth muscle, it appears that localized vascular-specific production is required for anticalcific effects. 16 Matrix gla protein's function as an inhibitor of calcification was demonstrated in the MGP knockout mouse when mice, normal at birth, developed abnormal cartilage and arterial calcification within a few weeks, which lead to arterial rupture and premature death. Subsequent work has shown that MGP expression specifically in the vasculature of MGP null mice prevents and even reverses arterial calcification. 16, 17 Warfarin is a vitamin K antagonist that interferes with vitamin K-dependent carboxylation and activation of MGP. Vitamin K is comprised of vitamin K 1 and vitamin K 2 . Vitamin K 1 appears to be most important for the activation of hepatic clotting factors, while vitamin K 2 is involved in the inhibition of calcium deposition in the vasculature. 18 Warfarin inhibition of vitamin K 1 blocks hepatic MGP carboxylation (K 1 ) leading to anticoagulation. Warfarin inhibition of vitamin K 2 affects vascular carboxylation promoting vascular calcification. Clinically, excessive calcification of coronary arteries and the aortic heart valve has been reported during warfarin treatment. [19] [20] [21] The populationbased Rotterdam Study found that vitamin K 2 intake (not vitamin K 1 intake) inversely correlated with cardiovascular calcification and cardiovascular death. 22 It is thought that genetic variation among individuals and differential g-carboxylation at the glutamate residues may lead to varying phenotypes and susceptibility to vascular calcification. 23 The clinical presentation with violaceous mottling or stellate-like livedo reticularis in the setting of warfarin therapy should arouse suspicion for warfarin-induced calciphylaxis. Slightly raised nodules or plaques with deep-purple skin discoloration might also be noted (Figures 1 and 2) . Patients will often have multiple lesions, and in 90% of patients, lesions are located on the limbs. 24 Intense cutaneous pain is frequently the most debilitating symptom patients experience and is often the sentinel symptom. 1 The differential diagnosis of these lesions includes disorders of platelet function, cold-related agglutination, vascular invasive organisms, coagulopathies, and cholesterol embolization in addition to miscellaneous others. 5, 25 No standard treatment exists for calciphylaxis. In 1 case series of 16 patients reported by Coates et al, the only 2 surviving patients were those with calciphylaxis in the setting of warfarin therapy and ESRD switched to therapeutic dose enoxaparin. 26 Warfarin should be discontinued immediately and an alternative anticoagulant should be started among patients on warfarin therapy with an atypical presentation for calciphylaxis.
One of the most critical elements in wound healing is oxygen supply to the wound. Local environmental factors in and around the wound including oxygen tension and vascular perfusion have a profound effect on healing. Wound hypoxia impairs essentially all the components of healing. 27 The small vessel calcification that promotes ischemia and leads to tissue necrosis has been demonstrated with transcutaneous oxygen tension measurements among patients with calciphylaxis. The wound environment becomes hypoxic and acidotic with high lactate levels. 28 Patients with calciphylaxis appear to have significantly lower tissue oxygen levels at all body regions. 12 Hyperbaric oxygenation may be a promising therapy among patients with calciphylaxis. Under atmospheric pressure, oxygen transport is limited by the oxygen-binding capacity of hemoglobin as minimal oxygen is transported by blood plasma. Hemoglobin is almost completely saturated with oxygen under atmospheric pressure and this route of oxygen transport cannot be exploited any further. Oxygen transport by plasma, however, is significantly increased under HBOT. The resultant increase in tissue partial pressure of oxygen enhances angiogenesis. 29, 30 Increased oxygenation promotes granulation, accelerates demarcation of the eschar, and is associated with wound healing and limb salvage. 30, 31 Hyperbaric oxygen therapy increases wound oxygen concentration, even in ischemic wounds, as long as there is some arterial inflow. [32] [33] [34] At the supraphysiologic tissue oxygen levels attained under hyperbaric conditions, wound healing continues after the treatment ends. Although wound oxygen tension decreases rapidly at the end of a treatment, levels do not return to baseline for several hours. 34, 35 There have recently been 2 case reports, and 2 case series highlighting the role of HBOT treatment of calciphylaxis. [29] [30] [31] 36 Podymow et al reported a series of 5 patients treated with between 25 and 35 hyperbaric sessions with complete healing in 2 patients having extensive necrotic ulcers. 31 Basile et al reported resolution of lesions among 8 of 9 patients treated with a mean of 40.6 sessions. 29 The duration of time from application of HBOT to wound resolution we observed (approximately 20 weeks) is similar to previous reports. 29, 31 The role of HBOT to treat calciphylaxis in patients with ESRD has been previously described. We report the first case of atypical calciphylaxis attributable to warfarin treated successfully with a therapeutic substitution of anticoagulant and HBOT. Although our patient presented with obesity and female gender as known risk factors for calciphylaxis, her modifiable risk factor was warfarin. Cessation of warfarin and application of HBOT promoted clinical resolution of her cutaneous lesions. Although no consensus exists for HBOT to treat hypoxic wound ulcers attributable to atypical calciphylaxis in the setting of warfarin therapy, we believe HBOT may represent a favorable therapy for this difficult disease.
Conclusion
The vitamin K antagonist warfarin has been described as a rare cause of calciphylaxis. Warfarin interferes with the activation of MGP, a local inhibitor of calcification in the vasculature. A high level of suspicion is required to diagnose atypical calciphylaxis attributable to warfarin. On diagnosis, immediate cessation of warfarin coupled with early wound care, pain management, and prevention of infection is essential. We report a case where warfarin cessation, anticoagulation with low-molecular-weight heparin, and HBOT successfully treated a patient with an atypical presentation of calciphylaxis.
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